Switch theme
Sign up to access all valuation multiples
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
2015
323
LTM Revenue $12.2M
LTM EBITDA -$334M
-$12.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Relay Therapeutics has a last 12-month revenue (LTM) of $12.2M and a last 12-month EBITDA of -$334M.
In the most recent fiscal year, Relay Therapeutics achieved revenue of $10.0M and an EBITDA of -$380M.
Relay Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Relay Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $12.2M | XXX | $10.0M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$334M | XXX | -$380M | XXX | XXX | XXX |
| EBITDA Margin | -2740% | XXX | -3799% | XXX | XXX | XXX |
| EBIT | -$333M | XXX | -$386M | XXX | XXX | XXX |
| EBIT Margin | -2731% | XXX | -3854% | XXX | XXX | XXX |
| Net Profit | -$302M | XXX | -$338M | XXX | XXX | XXX |
| Net Margin | -2483% | XXX | -3375% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Relay Therapeutics's stock price is $4.
Relay Therapeutics has current market cap of $610M, and EV of -$12.3M.
See Relay Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$12.3M | $610M | XXX | XXX | XXX | XXX | $-2.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Relay Therapeutics has market cap of $610M and EV of -$12.3M.
Relay Therapeutics's trades at -1.2x EV/Revenue multiple, and 0.0x EV/EBITDA.
Equity research analysts estimate Relay Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Relay Therapeutics has a P/E ratio of -2.0x.
See valuation multiples for Relay Therapeutics and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $610M | XXX | $610M | XXX | XXX | XXX |
| EV (current) | -$12.3M | XXX | -$12.3M | XXX | XXX | XXX |
| EV/Revenue | -1.0x | XXX | -1.2x | XXX | XXX | XXX |
| EV/EBITDA | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBIT | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.0x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRelay Therapeutics's last 12 month revenue growth is 1%
Relay Therapeutics's revenue per employee in the last FY averaged $31K, while opex per employee averaged $1.2M for the same period.
Relay Therapeutics's rule of 40 is -1463% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Relay Therapeutics's rule of X is -2737% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Relay Therapeutics and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -2740% | XXX | -3799% | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | -9% | XXX | XXX | XXX |
| Rule of 40 | -1463% | XXX | -3798% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2737% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $31K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3189% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3954% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Relay Therapeutics acquired XXX companies to date.
Last acquisition by Relay Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Relay Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Relay Therapeutics founded? | Relay Therapeutics was founded in 2015. |
| Where is Relay Therapeutics headquartered? | Relay Therapeutics is headquartered in United States of America. |
| How many employees does Relay Therapeutics have? | As of today, Relay Therapeutics has 323 employees. |
| Who is the CEO of Relay Therapeutics? | Relay Therapeutics's CEO is Dr. Sanjiv K. Patel, M.B.B.S.,M.D.. |
| Is Relay Therapeutics publicy listed? | Yes, Relay Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Relay Therapeutics? | Relay Therapeutics trades under RLAY ticker. |
| When did Relay Therapeutics go public? | Relay Therapeutics went public in 2020. |
| Who are competitors of Relay Therapeutics? | Similar companies to Relay Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Relay Therapeutics? | Relay Therapeutics's current market cap is $610M |
| What is the current revenue of Relay Therapeutics? | Relay Therapeutics's last 12 months revenue is $12.2M. |
| What is the current revenue growth of Relay Therapeutics? | Relay Therapeutics revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Relay Therapeutics? | Current revenue multiple of Relay Therapeutics is -1.0x. |
| Is Relay Therapeutics profitable? | Yes, Relay Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Relay Therapeutics? | Relay Therapeutics's last 12 months EBITDA is -$334M. |
| What is Relay Therapeutics's EBITDA margin? | Relay Therapeutics's last 12 months EBITDA margin is -2740%. |
| What is the current EV/EBITDA multiple of Relay Therapeutics? | Current EBITDA multiple of Relay Therapeutics is 0.0x. |
| What is the current FCF of Relay Therapeutics? | Relay Therapeutics's last 12 months FCF is -$251M. |
| What is Relay Therapeutics's FCF margin? | Relay Therapeutics's last 12 months FCF margin is -2060%. |
| What is the current EV/FCF multiple of Relay Therapeutics? | Current FCF multiple of Relay Therapeutics is 0.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
